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Background: Disruption of the transforming growth factor-beta (TGF-β) signaling pathway is observed in many
cancers, including cervical cancer, resulting in TGF-β resistance. While normal human keratinocytes (HKc) and
human papillomavirus type 16-immortalized HKc (HKc/HPV16) are sensitive to the growth inhibitory effects of
TGF-β, HKc/HPV16 develop resistance to TGF-β1 as they progress in vitro to a differentiation resistant phenotype
(HKc/DR). The loss of sensitivity to the antiproliferative effects of TGF-β1 in HKc/DR is due, at least partially, to
decreased expression of the TGF-β receptor type I. In the present study, we explored in detail whether alterations
in Smad protein levels, Smad phosphorylation, or nuclear localization of Smads in response to TGF-β could
contribute to the development of TGF-β resistance during in vitro progression of HKc/HPV16, and whether TGF-β
induction of a Smad-responsive reporter gene was altered in HKc/DR.
Methods: Western blot analysis was used to assess Smad protein levels. In order to study Smad nuclear
localization we performed indirect immunofluorescence. In addition, we determined Smad-mediated TGF-β
signaling using a luciferase reporter construct.
Results: We did not find a decrease in protein levels of Smad2, Smad3 or Smad4, or an increase in the inhibitory
Smad7 that paralleled the loss of sensitivity to the growth inhibitory effects of TGF-β1 observed in HKc/DR.
However, we found diminished Smad2 phosphorylation, and delayed nuclear Smad3 localization in response to
TGF-β1 in HKc/DR, compared to normal HKc and TGF-β sensitive HKc/HPV16. In addition, we determined that
TGF-β1 induction of a Smad responsive promoter is reduced by about 50% in HKc/DR, compared to HKc/HPV16.
Conclusions: These results demonstrate that alterations in Smad protein levels are not associated with the loss
of response to the antiproliferative effects of TGF-β in HKc/DR, but that diminished and delayed Smad
phosphorylation and nuclear localization, and decreased Smad signaling occur in response to TGF-β in HKc/DR.
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Transforming growth factor beta (TGF-β) is a multifunc-
tional cytokine involved in a variety of cellular processes
including cell proliferation, apoptosis, differentiation,
epithelial mesenchymal transition, angiogenesis, and
metastasis. The overall biological effects of TGF-β are
dependent on cell type and context [1-5]. Exposure of
most cell types to TGF-β, including epithelial, endothelial,* Correspondence: creekk@sccp.sc.edu
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reproduction in any medium, provided the orhematopoietic, neuronal cells, and primary mouse embry-
onic fibroblasts results in inhibition of cell proliferation
[6]. TGF-β exerts its effects by binding to receptors on the
plasma membrane that belong to the serine/threonine
kinase receptor family. Binding of TGF-β to TGF-β recep-
tor type II (TGFBR2) results in the recruitment of type I
TGF-β receptors (TGFBR1). This leads to the formation
of a membrane complex consisting of the TGF-β ligand
dimer, two TGFBR1 and two TGFBR2 receptors. Assem-
bly of this ligand/receptor complex brings the intracellular
domains of the receptors in very close proximity, facili-
tating transphosphorylation and activation of TGFBR1al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TGFBR1 then phosphorylates Smad2 and/or Smad3,
which are known as receptor regulated Smads. In their
phosphorylated state, the receptor-regulated Smads as-
sociate with Smad4, a co-Smad. The Smad complex
then migrates into the nucleus, where it interacts with
a variety of transcription factors, co-activators, co-
repressors and chromatin remodeling factors, and binds
to Smad-binding elements (SBEs) in the promoter re-
gion of target genes, thus regulating the transcription
of hundreds of genes [7-11].
Smad7, another protein involved in the TGF-β signaling
pathway, is an inhibitory Smad that acts as a negative
regulator of the pathway and has been reported to mediate
repression of the cytostatic effects of TGF-β [8]. Smad7
expression is induced by TGF-β signaling, thus acting
as a negative feedback loop that limits signaling. Smad7
competes with both Smad2 and Smad3 for binding to
the activated TGFBR1 and prevents their activation and
propagation of the signal into the nucleus [8].
A common characteristic of most human tumors is
the loss of sensitivity to the cytostatic effects of TGF-β,
which is believed to play an important role in tumor
progression and metastasis [12,13]. Alterations in many
components of the TGF-β signaling pathway, which lead
to TGF-β resistance, have been identified in a variety of
human malignancies. Among them are mutations in the
genes that encode the TGF-β receptors and Smad proteins,
and reduction or loss of TGFBR1, TGFBR2 and Smad
expression [12,14]. For example, a loss of Smad4 expres-
sion has been reported in cervical cancer tissue [15].
To study the cellular and molecular alterations associ-
ated with human papillomavirus type 16 (HPV16)-medi-
ated transformation we utilize an in vitro model where
normal human keratinocytes (HKc) are immortalized
by transfection with HPV16 DNA (HKc/HPV16). HKc/
HPV16 progress towards malignancy through several
phenotypically defined and reproducible stages that in-
clude growth factor independence (HKc/GFI), differen-
tiation resistance (HKc/DR), and ultimately malignant
conversion [16-20]. Previous studies in our laboratory
demonstrated that HKc/HPV16 are initially as sensitive
as normal HKc to the growth inhibitory effects of TGF-
β1, but become increasingly resistant during in vitro
progression [21]. A complete loss of the antiproliferative
effects of TGF-β1 is present in HKc/DR, which mimics
the TGF-β resistance observed in human cervical car-
cinoma cell lines [22,23]. In addition, we have previously
determined that the loss of growth inhibitory effects of
TGF-β1 in HKc/DR is associated with decreased expres-
sion of TGFBR1 mRNA and protein, while no change
in the expression of TGFBR2 mRNA was found. Im-
portantly, re-expression of TGFBR1 in HKc/DR fully
restored growth responses to TGFβ, suggesting that theobserved loss of TGFBR1 caused TGFβ resistance in
these cells [24,25].
The goal of the present study was to determine whether
alterations in protein levels, phosphorylation and nuclear
accumulation of Smads could also contribute to the re-
sistance to the antiproliferative effects of TGF-β1 that
we observe in HKc/DR. Overall, we found no loss of
Smad2, Smad3, Smad4, and no increase in Smad7 during
in vitro progression of HKc/HPV16. However, we found
a delay and a reduction in the phosphorylation of
Smad2 after TGF-β1 treatment in HKc/DR, as compared
to normal HKc and HKc/HPV16. In addition, we observed
a delay in nuclear accumulation of Smad3, and a 50%
reduction in the activation of Smad-dependent luciferase
expression in HKc/DR following TGF-β1 treatment.
Methods
Cell culture and cell lines
Foreskin specimens, derived from elective routine circum-
cision of neonate boys, were collected in a non-identified
fashion from a local hospital. The protocol for foreskin
tissue collection and use (PHA #2008-10) was reviewed
by the Palmetto Health (Columbia, SC) Institutional Re-
view Board, which determined that this protocol does
not constitute human subjects research because it uses
non-identified discarded surgical tissue.
Normal HKc were isolated as described previously [26].
Briefly, neonatal foreskins were collected in transport
medium: MCDB153-LB medium supplemented with 5%
fetal bovine serum (FBS) and 10 μg/ml gentamicin.
Connective tissue and fat were removed using a scalpel
and the cleaned foreskin was incubated with the epidermis
side facing up in 0.25% trypsin (Gibco BRL, Grand Island,
NY) diluted 4:1 in complete medium (CM) for 16 to 24 h
at 4°C (composition of CM is described below). Epidermis
was detached from the underlying dermis using sterile
forceps, chopped into small pieces and further disrupted
by gentle up and down pipetting in CM. HKc were col-
lected by centrifugation, resuspended into CM and plated
in 100-mm tissue culture dishes. Cells were incubated
in an atmosphere of 5% carbon dioxide and 95% air at
37°C. Media was changed 24 h post plating and every
48 h thereafter. CM consists of serum-free MCDB153-LB
medium supplemented with hydrocortisone (0.2 μM),
triiodothyronine (10 nM), transferrin (10 μg/ml), insu-
lin (5 μg/ml), epidermal growth factor (EGF) (5 ng/ml),
bovine pituitary extract (BPE) (35–50 μg/ml protein)
and gentamicin (50 μg/ml).
Normal HKc were immortalized by transfection with
a plasmid containing a dimer of the full-length HPV16
DNA sequence as described in detail previously [16,26].
HPV16 immortalized cells lines (HKc/HPV16) were de-
rived from four different foreskin donors and have been
designated HKc/HPV16-d1, -d2, -d4 and -d5 [16,26].
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factor independent cells (HKc/GFI) were selected in
CM lacking EGF and BPE, referred to as growth factor
depleted medium (GFDM). Furthermore, differentiation
resistant cells (HKc/DR) were obtained from HKc/GFI
that were selected in CM supplemented with 1.0 mM
calcium chloride and 5% FBS [16]. All cell lines were
routinely split 1:10 when confluent, medium was changed
24 h after passaging and every 48 h thereafter.
Preparation of total cellular protein extracts
Cells were grown to about 70% to 90% confluency in
100-mm tissue culture dishes and washed two times
with ice-cold phosphate-buffered saline (PBS). Cells were
then placed on ice and lysed in 400 μl of RIPA buffer
(50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, and 0.1% SDS) that was
supplemented with protease inhibitors (complete protease
inhibitor cocktail, Roche, Ltd.). Plates were scraped and
lysates collected into Eppendorf tubes and mixed for
1 min. After 30 min of incubation on ice, the lysates
were mixed again for 1 min and centrifuged at 14,000 × g
for 20 min at 4°C. The supernatants were aliquoted and
stored in a −80°C freezer until used. Samples used for
the assessment of phospho-Smad2 were lysed in RIPA
buffer that was supplemented with the protease inhibitor
cocktail and with the phosphatase inhibitors sodium
fluoride (50 mM) and sodium orthovanadate (1 mM).
Protein concentration determination in the cellular extracts
Protein concentrations of whole cell lysates were deter-
mined using the BCA Protein Assay Kit (Pierce, Part No.
23227) using a microplate format and according to the
manufacturer’s recommendations.
Western blot analysis
Cell lysates were mixed with 5× loading buffer; (Tris–
HCl (312.5 mM; pH 6.8), SDS (5%), glycerol (50%),
bromophenol blue (0.05%) and beta-mercaptoethanol
(β-ME) (25%)). All samples were then adjusted to equal
volumes with 1× loading buffer prepared by diluting 5×
loading buffer in RIPA buffer. Samples were denatured
at 100°C for 5 min and cooled on ice. Samples were
run using a 5% stacking gel and resolved on a 10%
SDS-polyacrylamide gel. Electrophoresis was performed
at 150 V for approximately 1 h using a Mini-PROTEAN II
gel apparatus (Bio-Rad Laboratories, Inc) and standard
running buffer (25 mM Tris base, 192 mM glycine and
0.1% SDS). The protein standards used for molecular
weight assessment were the Precision Plus Protein
Standards (Bio-Rad Laboratories). After electrophoresis,
the stacking gel was removed, the separating gel was
equilibrated for 10 min in refrigerated transfer buffer
(25 mM Tris, 192 mM glycine and 20% methanol) anda polyvinylidene fluoride (PVDF) membrane (Bio-Rad
Laboratories) was soaked in 100% methanol for 30 sec
and equilibrated in refrigerated transfer buffer for 10 min.
Proteins were transferred to the PVDF membrane at
80 mA during 16 h using transfer buffer at 4°C. After
completion of protein transfer, PVDF membranes were
briefly rinsed with 3 changes of PBS containing 0.05%
Tween 20 and then blocked at room temperature for 1.5 h
using a solution of 5% fat-free milk in the PBS-Tween
buffer. For membranes utilized for phospho-Smad2
detection the blocking buffer was supplemented with
sodium fluoride (50 mM). Membranes were then incu-
bated overnight at 4°C with primary antibody that was
diluted with fresh blocking solution, except for anti-
phospho-Smad2 antibody that was added to a solution
of 5% bovine serum albumin (BSA) in PBS-Tween. The
primary antibodies used were a mouse monoclonal anti-
Smad2 diluted 1:2,000 (L16D3; Cell Signaling Technology,
Inc.), a rabbit polyclonal anti-Smad3 diluted 1:1,000
(LPC3; Zymed), a mouse monoclonal anti-Smad4 di-
luted 1:5,000 (B-8; Santa Cruz Biotechnology, Inc.), a
rabbit polyclonal anti-Smad7 diluted 1:2,000 (ab5825;
Abcam, plc.), a rabbit polyclonal anti-actin diluted
1:20,000 (A2066, Sigma-Aldrich Co. LLC.) and a rabbit
monoclonal anti-phospho-Smad2 diluted 1:2,000 (138D4;
Cell Signaling Technology, Inc.). The rabbit monoclo-
nal anti-phospho-Smad2 antibody specifically detects
endogenous phosphorylated Smad2, with phosphates at
serines 465 and 467, which are the phosphorylation target
sites of the TGF-β-activated receptor kinase TGFBR1
[27]. Blots probed with anti-actin antibodies were used
to confirm equal protein loading. The membranes were
then washed at room temperature 5 times with 0.05%
Tween 20 in PBS for 5 min per wash and then were
incubated at room temperature for approximately 3 h
in either an anti-mouse (Vector Laboratories, Inc. - Cat.
No. PI-2000) or an anti-rabbit secondary antibody (Vector
Laboratories, Inc. - Cat. No. PI-1000). The secondary
antibodies were conjugated with horseradish peroxidase
(HRP) and were used at a 1:10,000 dilution in 5% fat-
free milk/PBS-Tween blocking buffer. A second series
of 5 washes at room temperature with 0.05% Tween 20 in
PBS for 5 min per wash were followed by chemilumines-
cence detection using ECL Western Blotting Detection Kit
(Amersham Biosciences), according to the manufacturer’s
instructions. Subsequently, membranes were placed on
X-OMAT AR films (Eastman Kodak) that were devel-
oped after exposure. Finally, quantitation of bands was
performed by densitometry using ImageJ software [28].
Preparation of TGF-β1 stocks and TGF-β1 treatment
A stock concentration of 10 μg/ml TGF-β1 was prepared
by adding 200 μl of 4 mM HCl solution containing
1 mg/ml BSA to a vial containing 2 μg of lyophilized
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No. 240-B). The TGF-β1 solution was aliquoted and
stored at −20°C until use. The TGF-β1 stock solution
was freshly diluted 10,000-fold in growth factor depleted
medium (GFDM) supplemented only with EGF, but not
with BPE (since BPE contains TGF-β) to obtain the 40
pM TGF-β1 concentration utilized in the experiments.
Cells investigated for phospho-Smad2 by Western blot-
ting were grown on 60-mm tissue culture dishes to
around 50-60% confluence and then incubated for 24 h
in BPE-free CM. Next, cells were treated for 0, 0.5, 1, 2,
4 and 6 h with 40 pM TGF-β1 in BPE-free CM and cell
lysates prepared as described above.
Immunofluorescence and confocal microscopy
Glass coverslips (12 mm) were pre-coated using a 0.01%
poly-L-lysine solution (Sigma-Aldrich Co. LLC, product
number P4707), according to the manufacturer recom-
mendations, and then placed into a 24-well tissue culture
plate where they were soaked overnight in media. The
next day normal HKc (10,000 cells), HKc/HPV16 (10,000
cells), or HKc/DR (5,000 cells) were plated on coverslips
and allowed to grow until about 50% confluence. Cells
were then incubated for 24 h in BPE-free CM and then
treated for 0, 5, 15, 30, and 60 min with 40 pM TGF-β1
in BPE-free CM.
Immediately after treatment, cells were rinsed 2 times
with ice-cold PBS and fixed for 30 min on ice with 4%
neutral paraformaldehyde in PBS. After fixation, cells were
washed with PBS (3 × 5 min) and then permeabilized
with a solution of Triton X-100 (0.1%) and glycine
(0.05 M) in PBS (2 × 10 min). Cells were washed with
PBS (2 × 2 min) and subsequently blocked for 45 min
with normal goat serum (5%) and BSA (1%) diluted in
PBS (blocking solution). A mouse monoclonal anti-Smad4
antibody (B-8; Santa Cruz Biotechnology, Inc.) was diluted
1:150 in 5-fold PBS-diluted blocking solution, added to
the cells, and then incubated overnight at 4°C. The fol-
lowing day, cells were washed with PBS (3 × 5 min) and
incubated at room temperature for 1 h in a secondary
antibody solution, which was prepared by diluting an
Alexa Fluor 488 (AF488) conjugated anti-mouse antibody
1:250 in 5-fold PBS diluted blocking solution. Cells
were rinsed with PBS (2 × 5 min) and then subjected to
a second round of staining for Smad3 using the same
conditions. The primary antibody used was a rabbit poly-
clonal anti-Smad3 diluted 1:200 (LPC3; Zymed) and the
secondary antibody was an anti-rabbit conjugated with
cyanine 3 (Cy3) diluted 1:250. After incubation with the
secondary antibody, cells were rinsed with PBS (2 ×
5 min); DNA was stained with DAPI (Molecular Probes)
for 15 min and rinsed again with PBS (3 × 5 min). Finally,
coverslips were mounted on glass slides using a DABCO
containing mounting media. The edges of the coverslipswere sealed with nail-polish and allowed to air dry. Cells
were imaged on a LSM Meta 510 confocal microscope
(Carl Zeiss, Inc.).
Nuclear Smad3 and nuclear Smad4 were later quanti-
fied in the acquired confocal pictures using ImageJ soft-
ware [28]. First, nuclear areas were determined using
threshold gating in the DAPI channel. The resulting
nuclear areas were then copied to both the Cy3 (Smad3)
and AF-488 (Smad4) channels and fluorescence inten-
sities, as well as corresponding areas, were quantified.
Intensities for each nucleus were then corrected to its
corresponding area. An average of 71 nuclei (range 56–
89) was quantified per time point per cell line. Finally,
absolute levels were converted to relative values within
each time course, having as reference (100%) the max-
imum level in the time course.
Transient transfection and luciferase assays
All four HKc/HPV16 and their corresponding HKc/DR
lines were plated in 6 well plates and transiently trans-
fected using TransFast (Promega, Madison, WI) in trip-
licate wells per experimental condition with p6SBE-Luc
or P6SME-Luc reporter constructs, along with pRL-
SV40 Renilla luciferase (Promega). The p6SBE-Luc and
p6SME-Luc constructs, which contain six intact (p6SBE)
or mutated (p6SME) Smad-binding-elements (SBE) cloned
into the pGL3 plasmid (Promega), were a gift of Dr. Scott
Kern. The next day, cells were treated without or with
40 pM TGF-β1 (R&D Systems). Cells were harvested
after 22 h of treatment and the lysate assayed for lucif-
erase activity using the Dual Luciferase Assay System
(Promega) according to manufacturer’s instructions. The
Firefly luciferase values, measured in Relative Light Units
(RLU), were normalized against Renilla luciferase activity
to control for transfection efficiency.
Results
Protein levels of Smad2, Smad3, Smad4 and Smad7 are
comparable among normal foreskin keratinocytes
established from different donors
We performed Western blot analysis in order to determine
whether or not basal protein levels of Smad2, Smad3,
Smad4 and Smad7 were comparable among foreskin kera-
tinocytes established from different donors. Protein levels
of Smad2, Smad3, Smad4, and Smad7 were comparable
among the eight individuals studied (data not shown).
Protein levels of Smad2, Smad3, Smad4 and Smad7 are
not dramatically changed during in vitro progression of
HPV16-immortalized human keratinocytes
We have previously reported that HKc/HPV16 progres-
sively become resistant to the antiproliferative effects of
TGF-β1 during in vitro progression through HKc/GFI
and HKc/DR stages [21,24]. To determine if altered
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may be a factor leading to TGF-β resistance, we studied
the steady state levels of the Smads by Western blot
analysis of whole cell lysates. We assessed Smad levels in
low and high passage HKc/HPV16, HKc/GFI, and HKc/
DR, in four independently established HKc/HPV16 lines
originating from different keratinocyte donors [16] in
comparison with normal HKc. Representative results are
shown in Figure 1. Smad2 and Smad3 protein levels
were found not to change during progression of HKc/
HPV16 (Figure 1A, 1B). We observed a consistent in-
crease of Smad4 protein expression in HKc/HPV16, HKc/
GFI, and HKc/DR compared to normal HKc (Figure 1C).
Finally, we found similar levels of Smad7 protein in HKc/
HPV16 and HKc/GFI compared to normal HKc, with
levels of Smad7 protein decreasing slightly in HKc/DR
(Figure 1D).
Nuclear trafficking of Smad3 and Smad4 after TGF-β1
treatment of normal HKc, HKc/HPV16 and HKc/DR
We next used indirect immunofluorescence microscopy
to compare the nuclear accumulation of Smad3 and
Smad4 in normal HKc, HKc/HPV16 and HKc/DR at
various times (0 to 60 min) following TGF-β1 treatment.
A representative example of the time course of the nuclear
accumulation of Smad3 and Smad4 following TGF-β1
treatment is shown in Figure 2 for HKc/HPV16. Nuclear
accumulation of Smad3 and Smad4 is evident as early as
5 min of TGF-β1 treatment, with marked nuclear accu-
mulation by 15 min, and sustained nuclear localization
up to 60 min (Figure 2). To quantify nuclear Smad3
and Smad4 accumulation over time in normal HKc and
all four HPV16 immortalized lines, we used ImageJFigure 1 Western blot analysis of Smads during in vitro progression o
from normal HKc, low passage (less than 40) and high passage (greater tha
blotting. Total protein (30 μg per well) was loaded and resolved in a 10% p
Smads were detected using anti-Smad antibodies: A – Smad2, B – Smad3,software to analyze the immunofluorescence images. For
comparison and normalization purposes, we set to 100%
the maximum nuclear fluorescence signal obtained for
Smad3 or Smad4 during the time course experiment. The
intensities observed at the other time points were then
expressed relative to the maximal intensity in each time
course. A representative time course is shown in Figure 3:
Smad3 began to accumulate into the nucleus as early as
5 min after the start of TGF-β1 treatment in normal HKc
(Figure 3A, panel 1) and HKc/HPV16 (Figure 3A, panel
2). Maximal nuclear Smad3 accumulation was observed
in normal HKc and HKc/HPV16 after 30 min of TGF-
β1 treatment (Figure 3A, panels 1 and 2). In contrast,
nuclear accumulation of Smad3 in HKc/DR was slightly
delayed. Nuclear Smad3 levels remained unchanged in
HKc/DR following 5 min of TGF-β1 treatment, although
maximal nuclear accumulation was still observed at 30 min
(Figure 3A, panel 3).
The time course of Smad4 nuclear accumulation was
similar among normal HKc, HKc/HPV16, and HKc/DR,
with maximal nuclear accumulation of Smad4 occurring
following 30 min of TGF-β1 treatment (Figure 3B,
panels 1–3).
Maximal Smad2 phosphorylation after TGF-β1 treatment
is delayed in HKc/DR as compared to normal HKc and
HKc/HPV16
We also investigated the kinetics of Smad2 phosphoryl-
ation after treatment with TGF-β1 in normal HKc, HKc/
HPV16, and HKc/DR. Smad2 phosphorylation was as-
sessed by Western blots of whole cell lysates from cells
treated for various times (0 to 6 h) with TGF-β1. The
maximum level of Smad2 phosphorylation in normalf HKc/HPV16. Smad protein levels in whole-cell extracts prepared
n 100) HKc/HPV16, HKc/GFI, and HKc/DR were determined by Western
olyacrylamide gel. After transferring proteins to PVDF membranes, the
C – Smad4, and D – Smad7. Actin was used as a loading control.
Figure 2 Nuclear accumulation of Smad3 and Smad4 in HKc/HPV16 after treatment with TGF-β. HKc/HPV16 were immunostained for
Smad3 (Cy3, red) and for Smad4 (Alexa Fluor 488, green) at various times (0 to 60 min) after treatment with 40 pM TGF-β. Nuclei were visualized
with DAPI (blue).
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β1 treatment and began to decline by 60 min (Figure 4,
panels A and B). In contrast, at 30 min HKc/DR had
reached only 87% of maximal Smad2 phosphorylation
and the peak of Smad2 phosphorylation did not occur
until 1 h of TGF-β1 treatment (Figure 4, panel C).
Densitometry analysis of multiple Western blots showed
that these results were reproducible across six normal
HKc strains examined, and four HKc/HPV16 lines with
their corresponding HKc/DR lines. These results dem-
onstrate that TGF-β1 signaling is somewhat delayed in
HKc/DR compared to normal HKc and HKc/HPV16.
Phosphorylation levels of Smad2 after TGF-β1 treatment
are reduced in HKc/DR as compared to normal HKc and
HKc/HPV16
We compared the extent of Smad2 phosphorylation to
total Smad2 protein in seven normal HKc strains derived
from different donors, and four HKc/HPV16 lines withtheir corresponding HKc/DR following treatment with
40 pM TGF-β1 for 6 h. We observed comparable levels
of Smad2 phosphorylation among the normal HKc strains,
four of which are shown in Figure 5. Also, comparable
levels of phospho-Smad2 between normal HKc and HKc/
HPV16 were observed (Figure 5, panels A and B). In con-
trast, Smad2 phosphorylation was reduced in HKc/DR as
compared to normal HKc and HKc/HPV16 (Figure 5,
panels A and B). The levels of total Smad2 protein ex-
pressed after 6 h of TGF-β1 treatment were comparable
among normal HKc, HKc/HPV16 and HKc/DR (Figure 5,
panels A and B).
TGF-β1 induction of a Smad-responsive luciferase
reporter construct in HKc/DR is reduced by approximately
50% in comparison with HKc/HPV16
Finally, we explored the ability of TGF-β1 to induce the
activity of a Firefly luciferase gene under the control of
the 6SBE element (p6SBE-Luc). As a control, we used a
Figure 3 Nuclear accumulation of Smad3 and Smad4 in normal HKc, HKc/HPV16 and HKc/DR following treatment with TGF-β. After
treatment with 40 pM TGF-β for various times (0 to 60 min), cells were immunostained for Smad3 (A) and Smad4 (B), and nuclei were visualized
with DAPI. Nuclear accumulation of Smad3 and Smad4 was determined using ImageJ software. 1 Normal HKc; 2 HKc/HPV16; 3 HKc/DR.
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which all six SBEs had been mutated (p6SME-Luc). No
induction of luciferase activity was detected in cells
transfected with p6SME-Luc and treated with TGF-β1
(data not shown). Induction of luciferase activity was
observed in all HKc/HPV16 and HKc/DR lines treated
with TGF-β1 (Figure 6). However, while luciferase in-
duction was 8- to 12-fold in HKc/HPV16, it was only
3.3- to 5.6-fold in HKc/DR.
Discussion
Our laboratory has developed an in vitro model of HPV16-
mediated human cell transformation in which normal
HKc transfected with HPV16 DNA, HKc/HPV16, pro-
gress towards malignancy through HKc/GFI and HKc/
DR stages [16-18]. HKc/HPV16 are initially as sensitive
to the cytostatic effects of TGF-β1 as normal HKc but
become increasingly resistant to the antiproliferative
effects of TGF-β1 during in vitro progression [21]. We
have previously linked resistance to growth control
by TGF-β1 at the HKc/DR stage to reduced mRNAexpression of TGFBR1 but not TGFBR2 [24]. Reduced
mRNA expression of TGFBR1 in HKc/DR is not the
result of mutations in or hypermethylation of the TGFBR1
promoter, or of changes in the protein levels of the
transcription factors Sp1 or Sp3, which drive TGFBR1
expression [25]. The Smads are the intracellular mediators
of TGF-β signaling [7,8,10,11]. The goal of the present
study was to explore whether alterations in Smad protein
levels, as HKc/HPV16 progress through the HKc/GFI
and HKc/DR stages, may contribute to the loss of sen-
sitivity to the growth inhibitory effects of TGF-β. In
addition, we studied nuclear trafficking of Smad3 and
Smad4 in HKc/HPV16 and HKc/DR as well as the kinetics
of Smad2 phosphorylation in these cells following TGF-β1
treatment.
Smad2 mRNA expression has been found reduced in
22% of cervical carcinomas, as compared to normal
cervix [29], while another study reported “weak” Smad2
protein levels in 33% of cervical tumors [30]. However,
no association between Smad2 protein expression in
cervical tumors and clinicopathological characteristics
Figure 4 Time course of Smad2 phosphorylation after TGF-β treatment of normal HKc, low-passage HKc/HPV16 and HKc/DR. Normal
HKc, low-passage (< 40) HKc/HPV16 and HKc/DR were treated with 40 pM TGF-β for the times indicated. Whole-cell lysates were analyzed for
phospho-Smad2 by Western blot analysis. Total protein (25 μg/well) was loaded and resolved in a 10% polyacrylamide gel. After transfer to a
PVDF membrane, phospho-Smad2 was detected with a rabbit anti-human phospho-Smad2 antibody. Representative time courses are shown for
normal HKc (panel A), low-passage (<40) HKc/HPV16 (panel B) and HKc/DR (panel C). Actin was used as a loading control.
Altomare et al. BMC Cancer 2013, 13:424 Page 8 of 12
http://www.biomedcentral.com/1471-2407/13/424such as lymph node status, tumor size, disease recurrence,
degree of infiltration and HPV type was found [30]. In
our in vitro model system we observed no significant
reduction of Smad2 protein expression as the cells pro-
gress through the HKc/GFI and HKc/DR stages. Thus, we
conclude that a reduction in Smad2 does not contribute
to the progressive loss of sensitivity to the antiproliferative
effects of TGF-β1 that we observe as HKc/HPV16 pro-
gress in vitro [21]. These findings could suggest that
decreased protein levels of Smad2 found in cervical car-
cinomas is a late event in HPV-mediated disease [30]. This
view is supported by our finding that, although differenti-
ation resistant, HKc/DR are not tumorigenic [19,20].Mutation of the Smad3 gene is very rarely found in
human cancer [31]. However, the finding that Smad3
protein is absent in T-cell acute lymphoblastic leukemia
(T-ALL), which results in an impaired inhibitory effect
of TGF-β on T-cell proliferation, supports the notion of
a tumor-suppressing role of Smad3 in at least this
disease. Interestingly, the loss of Smad3 in T-ALL is not
caused by either mutation or a decrease in its mRNA
expression [32]. More evidence supporting the tumor-
suppressing role of Smad3 comes from experiments with
Smad3-deficient mice, where Smad3 deficiency alone is
not enough to initiate tumorigenesis, but decreased
Smad3 expression augmented the risk of tumorigenesis
Figure 5 Western blot analysis of Smad2 phosphorylation in normal HKc, HKc/HPV16, and HKc/DR after 6 h of TGF-β treatment.
Normal HKc, low-passage (< 40) HKc/HPV16, and HKc/DR were treated for 6 h with 40 pM TGF-β. Whole-cell extracts were collected and total
protein (25 μg/well) was resolved in a 10% polyacrylamide gel. A rabbit anti-phospho-Smad2 antibody, a mouse anti-Smad2 monoclonal
antibody, and a rabbit anti-actin polyclonal antibody were utilized to detect phospho-Smad2, total Smad2, and actin, respectively. Panel A shows
two normal HKc strains, and HKc/HPV16 and HKc/DR from two donors (d1 and d2). Panel B shows the results from two additional normal HKc
strains, as well as HKc/HPV16 and HKc/DR from two additional donors (d4 and d5).
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in cellular proliferation and apoptosis [33,34]. In addition
to its inhibitory role on cell proliferation, Smad3 can
exert a tumor suppression function in hepatic cells by
downregulating the antiapoptotic protein BCL2, which
results in TGF-β-mediated apoptosis [35]. In our model
of HPV16-mediated transformation, we did not find a
consistent reduction of Smad3 protein levels as the
cells progress in vitro. Therefore, alterations of Smad3
protein levels are not likely involved in the progressive
reduction of the growth inhibitory response to TGF-β
that takes place in this model.Figure 6 TGF-β activation of a Smad-responsive luciferase
reporter construct in HKc/HPV16 and HKc/DR. Four HKc/HPV16
and their corresponding HKc/DR lines (d-1, d-2, d-4 and d-5) were
transiently transfected in triplicate wells per experimental condition
with the p6SBE-Luc reporter construct and pRL-SV40. Cells were
allowed to grow in CM for 24 h after transfections. Following this,
they were treated without or with 40 pM TGF-B1 for 22 h and
harvested for luciferase activity. Firefly luciferase values, measured in
Relative Light Units (RLU), were normalized against Renilla luciferase
values, and the results expressed as fold induction over control.Another protein involved in the transmission of TGF-
β signaling from the plasma membrane to nucleus is
Smad4 [7-11]. Studies have found homozygous deletions
of Smad4 in 30% of pancreatic tumors, and inactivating
intragenic mutation in conjunction with loss of the other
allele in another 20% of cases [36]. Mutations of the
Smad4 gene in other tumor types are less frequent, with
a 16% rate in biliary tract cancers, 13% in colorectal
carcinomas, 12% in breast cancers, bladder cancers and
ovarian cancers, 7% in lung cancers, 6% in hepatocellular
carcinoma and 4% in cervical cancers [14]. Studies in
cervical tissue have shown similar levels of Smad4
mRNA expression in non-malignant and premalignant
tissue. However, Smad4 expression is decreased or lost
in 90% of cervical squamous cell carcinomas [15]. An
immunohistological study in cervical squamous cell car-
cinomas revealed a significant correlation of weak cyto-
plasmic Smad4 staining with both the presence of
positive lymph nodes and recurrent disease [30]. Fur-
thermore, absence of nuclear Smad4 protein expression
strongly correlated with tumors size and infiltration
depth [30]. Both weak cytoplasmic Smad4 and the ab-
sence of nuclear Smad4 staining were associated with
poor survival in cervical cancer patients [30]. The
HPV16-positive SiHa human cervical carcinoma cell
line is refractory to growth inhibition by TGF-β, which
is explained, at least in part, by reduced expression of
Smad4 in these cells [37]. Transfection of SiHa with a
Smad4 expression construct recovered the growth-in-
hibitory effects of TGF-β in these cells [37]. Our studies
of Smad4 protein expression in our in vitro model of
HPV16-mediated transformation indicate that immortal-
ization by HPV16 DNA triggers an early increase in
Smad4 protein in HKc/HPV16, as compared to normal
HKc, and this increase is maintained at later stages of
in vitro progression. The functional significance of this
finding remains to be determined.
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signaling. Both deletions and amplifications of the Smad7
gene have been reported in colorectal tumors [14]. None-
theless, amplifications are more common than deletions,
as compared to the same genetic alterations of Smad2
and Smad4, which suggests that retention and even
amplification of Smad7 is the selected event during
colorectal tumorigenesis [14]. These findings are in
agreement with frequent Smad7 overexpression found
in endometrial and thyroid follicular carcinomas [14].
Studies have also found upregulation of Smad7 mRNA
in pancreatic cancer as compared to normal tissue [38].
Furthermore, transfection of Smad7 into the TGF-β sensi-
tive pancreatic cell line COLO-357 rendered them re-
fractory to the antiproliferative effect of the cytokine,
and drastically enhanced soft agar colony formation
[38]. In another study, primary mouse keratinocytes were
transduced with the Smad7 gene resulting in enhanced
keratinocyte proliferation, blocked normal differentiation,
and induced keratin 8, a marker of malignant conversion,
but did not result in tumor formation [39]. When Smad7
was transduced together with HRAS, keratinocytes rapidly
progressed to squamous cell carcinomas in vivo, whereas
transduction with HRAS together with Smad6 or an
empty vector control resulted in benign papillomas [39].
These findings demonstrate that Smad7 overexpression
can accelerate tumor progression and cause malignant
conversion in the context of other oncogenes [39].
Although no alterations in the Smad7 gene have been
described in cervical cancer, we investigated if increased
Smad7 levels could play a role in the progressive loss of
growth inhibitory response to TGF-β1 that we observed
as HKc/HPV16 progress to the HKc/DR stage. We found
similar levels of Smad7 protein in HKc/HPV16 and HKc/
GFI compared to normal HKc, with levels of Smad7
protein decreasing slightly in HKc/DR. Thus, our data
do not support a role for Smad7 overexpression in
TGF-β1 resistance in HKc/DR.
Many studies have demonstrated that activated
TGFBR1 phosphorylates Smad2 and Smad3 resulting in
formation of Smad4-containing heteromeric complexes
that are translocated to the nucleus, where they drive
transcriptional responses [11,40]. TGF-β treatment of un-
transfected Mv1Lu mink lung epithelial cells resulted
in phosphorylation, nuclear shuttling and nuclear accu-
mulation of Smad2 and Smad3 [11]. In addition, Smad4
also accumulated into the nucleus paralleling Smad2
and Smad3 shuttling [11]. Similarly, the spontaneously-
immortalized TGF-β-responsive human keratinocyte Ha
CaT cell line accumulates Smad2/3 and Smad4 in the
nucleus after treatment with TGF-β [41]. The peak of
Smad2/3 nuclear accumulation and Smad2 phosphoryl-
ation takes place as early as 30 min following TGF-β
treatment [41]. Additionally, experiments have demon-strated that TGF-β-treated cell lines expressing higher
levels of TGFBR1 maintained nuclear accumulation of
Smad2, Smad3 and Smad4 proteins, as well as Smad2
phosphorylation, for up to 6 h [42]. In contrast, nuclear
accumulation of these Smads and phosphorylation of
Smad2 could be maintained for only 1 or 2 h in other
cell lines, which could be explained, at least in part, by
the low expression of TGFBR1 in these cells [42].
Previous experiments in our laboratory found that a
progressive loss of sensitivity to the growth inhibitory
effects of TGF-β1, as HKc/HPV16 progress to the HKc/
DR stage, strongly correlates with decreased expression
of TGFBR1 messenger RNA and protein [24]. In order
to further explore alterations in TGF-β signaling in our
model system, we studied the kinetics of Smad3 and
Smad4 nuclear accumulation, as well as the levels of
Smad2 phosphorylation following TGF-β1 treatment.
We observed a delay in Smad3 nuclear accumulation in
HKc/DR as compared to normal HKc and HKc/HPV16;
maximal Smad2 phosphorylation was also delayed in
HKc/DR. Furthermore, the level of Smad2 phosphoryl-
ation after 6 h of TGF-β1 treatment was decreased in
all four HKc/DR lines we studied, as compared to their
HKc/HPV16 counterparts and to normal HKc. In con-
trast, nuclear accumulation of Smad4 was not delayed.
These results indicate that the Smad system is mostly
intact in HKc/DR: it is likely that the alterations we
observe in Smad2 phosphorylation are a direct conse-
quence of the loss of TGFBR1. To further assess the
status of Smad signaling in HKc/DR, we compared the
TGF-β1-induced activity of a luciferase reporter construct
under the transcriptional control of six in-tandem SBEs
in HKc/HPV16 and their corresponding HKc/DR [43].
These experiments showed that Smad-mediated TGF-
β1 transcriptional activation is reduced by about 50% in
HKc/DR, as compared to HKc/HPV16.
Conclusions
In summary, our findings demonstrate that although HKc/
DR are completely resistant to the growth inhibitory effects
of TGF-β1 [24], the Smad pathway remains relatively intact
in HKc/DR, including Smad translocation to the nucleus
following TGF-β1 treatment, and partial induction of a
luciferase reporter construct driven by 6SBEs. We will
continue to utilize our in vitro model system for HPV16-
mediated transformation and progression, which shares
many gene expression changes with those found in pre-
malignant cervical lesions and cervical cancer [44] to
explore why HKc/DR are no longer responsive to the
growth inhibitory effects of TGF-β1, even though substan-
tial Smad signaling remains.
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